{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:39:21Z","timestamp":1776400761277,"version":"3.51.2"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:09:20Z","timestamp":1752937760000},"page":"e969-e975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9355-1298","authenticated-orcid":false,"given":"Viviane","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivetha","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Dusza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-1057","authenticated-orcid":false,"given":"Shamir","family":"Geller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2025.07.011_bib0001","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.07.011_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.07.011_bib0003","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.clml.2025.07.011_bib0004","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.07.011_bib0005","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.07.011_bib0006","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2024-203577","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma: final results from the phase 2 PRIMO trial","volume":"144","author":"Mehta-Shah","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.07.011_bib0007","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.clml.2025.07.011_bib0008","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamaoncol.2019.0034","article-title":"Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: a review","volume":"5","author":"Esposito","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.07.011_bib0009","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2022.4327","article-title":"Incidence of cutaneous adverse events with phosphoinositide 3-kinase inhibitors as adjuvant therapy in patients with cancer: a systematic review and meta-analysis","volume":"8","author":"Jfri","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.clml.2025.07.011_bib0011","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant T cells","volume":"5","author":"Valdez","year":"2015","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.clml.2025.07.011_bib0012","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.07.011_bib0013","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12967-024-05617-6","article-title":"Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.clml.2025.07.011_bib0014","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamadermatol.2024.4582","article-title":"Successful treatment of mogamulizumab-associated rash with Upadacitinib: evidence from 2 cases","volume":"161","author":"Mart\u00edn-Torregrosa","year":"2025","journal-title":"JAMA Dermaol"},{"key":"10.1016\/j.clml.2025.07.011_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jdcr.2023.06.009","article-title":"Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor","volume":"38","author":"Lama","year":"2023","journal-title":"JAAD Case Rep"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:39:09Z","timestamp":1776397149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025002551"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}